Synthetic Biology Lures Silicon Valley Investors

November 5, 2015

(Nature) – Three years later, Silicon Valley’s big fish — technology investors with billions of dollars at their disposal — have finally ventured into synthetic biology’s small pond. Scared away from conventional biotechnology in past by the risky and expensive prospect of drug development, they are now lured by what they see as synthetic biology’s huge market potential, plummeting operating costs, improved business models and an increasing emphasis on computing.